Personalized medicine in CLL: Current status and future perspectives
Highlights • While CLL is still considered an incurable disease, the clinical course is extremely variable. Therefore, an individualized approach is needed. • Cytogenetic studies including FISH provide valuable prognostic information and are recommended in all newly diagnosed CLL patients. • The pre...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2014-09, Vol.352 (1), p.4-14 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 1 |
| container_start_page | 4 |
| container_title | Cancer letters |
| container_volume | 352 |
| creator | Rozovski, Uri Hazan-Halevy, Inbal Keating, Michael J Estrov, Zeev |
| description | Highlights • While CLL is still considered an incurable disease, the clinical course is extremely variable. Therefore, an individualized approach is needed. • Cytogenetic studies including FISH provide valuable prognostic information and are recommended in all newly diagnosed CLL patients. • The presence of somatic mutations in IGHV, expression of ZAP-70 or CD38, and serum levels of β2M, or thymidine kinase are also of prognostic value. • Several tyrosine kinase inhibitors currently being investigated in CLL induce responses in patients with chemotherapy-refractory disease. • In the future, integrated clinical and genetic information will guide personalized, curative therapy. |
| doi_str_mv | 10.1016/j.canlet.2013.07.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3871981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383513005338</els_id><sourcerecordid>3401148701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c616t-1dfee57c4a30824a9728b8a43cb3e0bef8f1c2cfc7255aa8997c62f279918c663</originalsourceid><addsrcrecordid>eNqFUkuP0zAQthCILQv_AKFIXLgk-JHEDgekVXlKlUACziN3OgGX1Cl2Umn59Uzpsgt74TSW8s2X7zFCPFayUlK1z7cV-jjQVGmpTCVtxeOOWChndWk7J--KhTSyLo0zzZl4kPNWStnUtrkvzrRxtutatRCvPlLKY_RD-EmbYkebgCFSEWKxXK1eFMs5JYpTkSc_zbnwcVP08zQnKva8tyecwoHyQ3Gv90OmR1fzXHx58_rz8l25-vD2_fJiVWKr2qlUm56osVh7I52ufWe1WztfG1wbkmvqXa9QY49WN433russtrrXLFU5bFtzLl6eePfzmqUiK0t-gH0KO58uYfQB_v0Swzf4Oh6A7arOKSZ4dkWQxh8z5Ql2ISMNg480zhlU0xgrOT3L0Ke3oNtxThzUb5R2nbG1Y1R9QmEac07UX4tREo41wRZONcGxJpAWePDak7-NXC_96eXGKXGch0AJMgaKyP0kDh02Y_jfH24T4BBiQD98p0vKN14ga5Dw6Xgqx0tRho_E8OsXUxO6vQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552893748</pqid></control><display><type>article</type><title>Personalized medicine in CLL: Current status and future perspectives</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rozovski, Uri ; Hazan-Halevy, Inbal ; Keating, Michael J ; Estrov, Zeev</creator><creatorcontrib>Rozovski, Uri ; Hazan-Halevy, Inbal ; Keating, Michael J ; Estrov, Zeev</creatorcontrib><description>Highlights • While CLL is still considered an incurable disease, the clinical course is extremely variable. Therefore, an individualized approach is needed. • Cytogenetic studies including FISH provide valuable prognostic information and are recommended in all newly diagnosed CLL patients. • The presence of somatic mutations in IGHV, expression of ZAP-70 or CD38, and serum levels of β2M, or thymidine kinase are also of prognostic value. • Several tyrosine kinase inhibitors currently being investigated in CLL induce responses in patients with chemotherapy-refractory disease. • In the future, integrated clinical and genetic information will guide personalized, curative therapy.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2013.07.013</identifier><identifier>PMID: 23879961</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Chromosomes ; CLL ; Decision making ; Drug therapy ; Hematology, Oncology and Palliative Medicine ; Humans ; Immunotherapy - trends ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Mutation ; Personalized medicine ; Precision medicine ; Precision Medicine - standards ; Precision Medicine - trends ; Targeted therapy</subject><ispartof>Cancer letters, 2014-09, Vol.352 (1), p.4-14</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2013 Elsevier Ireland Ltd</rights><rights>Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 28, 2014</rights><rights>2013 Elsevier Ireland Ltd. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c616t-1dfee57c4a30824a9728b8a43cb3e0bef8f1c2cfc7255aa8997c62f279918c663</citedby><cites>FETCH-LOGICAL-c616t-1dfee57c4a30824a9728b8a43cb3e0bef8f1c2cfc7255aa8997c62f279918c663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383513005338$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23879961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rozovski, Uri</creatorcontrib><creatorcontrib>Hazan-Halevy, Inbal</creatorcontrib><creatorcontrib>Keating, Michael J</creatorcontrib><creatorcontrib>Estrov, Zeev</creatorcontrib><title>Personalized medicine in CLL: Current status and future perspectives</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • While CLL is still considered an incurable disease, the clinical course is extremely variable. Therefore, an individualized approach is needed. • Cytogenetic studies including FISH provide valuable prognostic information and are recommended in all newly diagnosed CLL patients. • The presence of somatic mutations in IGHV, expression of ZAP-70 or CD38, and serum levels of β2M, or thymidine kinase are also of prognostic value. • Several tyrosine kinase inhibitors currently being investigated in CLL induce responses in patients with chemotherapy-refractory disease. • In the future, integrated clinical and genetic information will guide personalized, curative therapy.</description><subject>Chromosomes</subject><subject>CLL</subject><subject>Decision making</subject><subject>Drug therapy</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immunotherapy - trends</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Mutation</subject><subject>Personalized medicine</subject><subject>Precision medicine</subject><subject>Precision Medicine - standards</subject><subject>Precision Medicine - trends</subject><subject>Targeted therapy</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUkuP0zAQthCILQv_AKFIXLgk-JHEDgekVXlKlUACziN3OgGX1Cl2Umn59Uzpsgt74TSW8s2X7zFCPFayUlK1z7cV-jjQVGmpTCVtxeOOWChndWk7J--KhTSyLo0zzZl4kPNWStnUtrkvzrRxtutatRCvPlLKY_RD-EmbYkebgCFSEWKxXK1eFMs5JYpTkSc_zbnwcVP08zQnKva8tyecwoHyQ3Gv90OmR1fzXHx58_rz8l25-vD2_fJiVWKr2qlUm56osVh7I52ufWe1WztfG1wbkmvqXa9QY49WN433russtrrXLFU5bFtzLl6eePfzmqUiK0t-gH0KO58uYfQB_v0Swzf4Oh6A7arOKSZ4dkWQxh8z5Ql2ISMNg480zhlU0xgrOT3L0Ke3oNtxThzUb5R2nbG1Y1R9QmEac07UX4tREo41wRZONcGxJpAWePDak7-NXC_96eXGKXGch0AJMgaKyP0kDh02Y_jfH24T4BBiQD98p0vKN14ga5Dw6Xgqx0tRho_E8OsXUxO6vQ</recordid><startdate>20140928</startdate><enddate>20140928</enddate><creator>Rozovski, Uri</creator><creator>Hazan-Halevy, Inbal</creator><creator>Keating, Michael J</creator><creator>Estrov, Zeev</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140928</creationdate><title>Personalized medicine in CLL: Current status and future perspectives</title><author>Rozovski, Uri ; Hazan-Halevy, Inbal ; Keating, Michael J ; Estrov, Zeev</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c616t-1dfee57c4a30824a9728b8a43cb3e0bef8f1c2cfc7255aa8997c62f279918c663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Chromosomes</topic><topic>CLL</topic><topic>Decision making</topic><topic>Drug therapy</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immunotherapy - trends</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Mutation</topic><topic>Personalized medicine</topic><topic>Precision medicine</topic><topic>Precision Medicine - standards</topic><topic>Precision Medicine - trends</topic><topic>Targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rozovski, Uri</creatorcontrib><creatorcontrib>Hazan-Halevy, Inbal</creatorcontrib><creatorcontrib>Keating, Michael J</creatorcontrib><creatorcontrib>Estrov, Zeev</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rozovski, Uri</au><au>Hazan-Halevy, Inbal</au><au>Keating, Michael J</au><au>Estrov, Zeev</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Personalized medicine in CLL: Current status and future perspectives</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2014-09-28</date><risdate>2014</risdate><volume>352</volume><issue>1</issue><spage>4</spage><epage>14</epage><pages>4-14</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights • While CLL is still considered an incurable disease, the clinical course is extremely variable. Therefore, an individualized approach is needed. • Cytogenetic studies including FISH provide valuable prognostic information and are recommended in all newly diagnosed CLL patients. • The presence of somatic mutations in IGHV, expression of ZAP-70 or CD38, and serum levels of β2M, or thymidine kinase are also of prognostic value. • Several tyrosine kinase inhibitors currently being investigated in CLL induce responses in patients with chemotherapy-refractory disease. • In the future, integrated clinical and genetic information will guide personalized, curative therapy.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>23879961</pmid><doi>10.1016/j.canlet.2013.07.013</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2014-09, Vol.352 (1), p.4-14 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3871981 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Chromosomes CLL Decision making Drug therapy Hematology, Oncology and Palliative Medicine Humans Immunotherapy - trends Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - therapy Mutation Personalized medicine Precision medicine Precision Medicine - standards Precision Medicine - trends Targeted therapy |
| title | Personalized medicine in CLL: Current status and future perspectives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T01%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Personalized%20medicine%20in%20CLL:%20Current%20status%20and%20future%20perspectives&rft.jtitle=Cancer%20letters&rft.au=Rozovski,%20Uri&rft.date=2014-09-28&rft.volume=352&rft.issue=1&rft.spage=4&rft.epage=14&rft.pages=4-14&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2013.07.013&rft_dat=%3Cproquest_pubme%3E3401148701%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552893748&rft_id=info:pmid/23879961&rft_els_id=1_s2_0_S0304383513005338&rfr_iscdi=true |